Valerio Therapeutics Terminates Liquidity Contract with Kepler Cheuvreux

Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company specializing in DNA-decoy therapies, has announced the termination of its liquidity contract with Kepler Cheuvreux. The contract, entered into on October 29, 2018, was terminated on February 19, 2025, as part of the company's efforts to save resources given its cash position. The termination was decided as part of the company's strategic focus on cost optimization and financial management.

The termination of the liquidity contract has had an impact on Valerio Therapeutics' stock performance and market capitalization. The company's stock price has been volatile in recent weeks, with a decline of 2.86% on February 25, 2025, compared to the previous day. The company's market capitalization has also been affected, with a decline of 2.86% on February 25, 2025, compared to the previous day. This decline in market capitalization may be attributed to the termination of the liquidity contract, as well as other factors such as the company's financial performance and market conditions.

The termination of the liquidity contract may have potential implications for investors. The reduced liquidity of the company's shares may make it more difficult for investors to buy and sell shares, which could impact the company's ability to raise capital and attract new investors. Additionally, the decline in the company's stock price and market capitalization may make the company less attractive to potential investors.

Valerio Therapeutics has not explicitly stated any alternative financing or liquidity options it is exploring to ensure its financial stability and growth. However, the company could consider equity financing, debt financing, strategic partnerships, government grants and subsidies, and revenue growth to ensure its financial stability and growth. The company should carefully evaluate each option and consider its specific needs, resources, and constraints when making a decision.



In conclusion, Valerio Therapeutics' termination of its liquidity contract with Kepler Cheuvreux has had an impact on the company's stock performance and market capitalization, and may have potential implications for investors. The company should consider alternative financing or liquidity options to ensure its financial stability and growth. Investors should closely monitor the company's financial performance and market conditions to make informed investment decisions.